Evotec
Sonia Carulli is a seasoned professional in the field of cell therapy and regenerative medicine, currently serving as a Senior Scientist in Cell Therapy Process Development at Evotec since February 2023. Prior experience includes a role as a GMP Production Scientist at Holostem Terapie Avanzate S.r.l. from April 2015 to February 2023, where responsibilities encompassed the manufacturing of Advanced Therapy Medicinal Products (ATMPs) under GMP standards, particularly in aseptic environments for cell and gene therapy applications. Additionally, a post-doctoral fellowship at Centro di Medicina Rigenerativa “Stefano Ferrari” focused on characterizing epidermal stem cells and gene therapy approaches for Epidermolysis Bullosa. Sonia holds a PhD in Biologia Cellulare e Molecolare from Université Claude Bernard Lyon 1 and has completed studies at key institutions, including Institut de Biologie et Chimie des Protèines and Università degli Studi di Modena e Reggio Emilia.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.